Prolactin-secreting tumours (prolactinomas) represent the most common pituitary tumour type, accounting for 47-66% of functional pituitary tumours. Prolactinomas are usually benign and controllable tumours as they express abundant levels of dopamine type 2 receptor (D2), and can be treated with dopaminergic drugs, effectively reducing prolactin levels and tumour volume. However, a proportion of prolactinomas exhibits aggressive features (including invasiveness, relevant growth despite adequate dopamine agonist treatment and recurrent potential) and few may exhibit metastasizing potential (carcinomas). In this context, the clinical, pathological and molecular definitions of malignant and aggressive prolactinomas is still to be clearly defined, as primary prolactin-secreting carcinomas are similar to aggressive adenomas until the presence of metastases is detected. Indeed, standard molecular and histological analyses do not reflect differences between carcinomas and adenomas at a first glance and have limitations to predict the aggressive progression of prolactinomas, wherein the causes underlying the aggressive behaviour remain unknown. Herein we present a comprehensive, multidisciplinary review of the most relevant epidemiological, clinical, pathological, genetic, biochemical and molecular aspects of aggressive and malignant prolactinomas..

Aggressive and malignant prolactinomas

Gatto, Federico;
2019-01-01

Abstract

Prolactin-secreting tumours (prolactinomas) represent the most common pituitary tumour type, accounting for 47-66% of functional pituitary tumours. Prolactinomas are usually benign and controllable tumours as they express abundant levels of dopamine type 2 receptor (D2), and can be treated with dopaminergic drugs, effectively reducing prolactin levels and tumour volume. However, a proportion of prolactinomas exhibits aggressive features (including invasiveness, relevant growth despite adequate dopamine agonist treatment and recurrent potential) and few may exhibit metastasizing potential (carcinomas). In this context, the clinical, pathological and molecular definitions of malignant and aggressive prolactinomas is still to be clearly defined, as primary prolactin-secreting carcinomas are similar to aggressive adenomas until the presence of metastases is detected. Indeed, standard molecular and histological analyses do not reflect differences between carcinomas and adenomas at a first glance and have limitations to predict the aggressive progression of prolactinomas, wherein the causes underlying the aggressive behaviour remain unknown. Herein we present a comprehensive, multidisciplinary review of the most relevant epidemiological, clinical, pathological, genetic, biochemical and molecular aspects of aggressive and malignant prolactinomas..
File in questo prodotto:
File Dimensione Formato  
Olarescu N et al. Neuroendocrinology 2019.pdf

accesso chiuso

Tipologia: Documento in versione editoriale
Dimensione 364.42 kB
Formato Adobe PDF
364.42 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11567/941454
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 16
social impact